Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amlodipine augmentation for late-life unremitted vascular depression
2010-023969-21Phase 3Completed
- Sponsor
- Gateshead Health NHS Foundation Trust
- Start
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in vascular depression (VD) and major depressive disorder (MDD) comparing Amlodipine augmentation with Placebo augmentation (2 arms). Primary endpoint: Remission by 16 weeks. Started Sep 2011; status: completed.
02
Drugs
amlodipine
03
Conditions
vascular depression (VD)major depressive disorder (MDD)
Beyond the preview
Go deeper on 2010-023969-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023969-21.